KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $3.9 million.

  • Pacira BioSciences' Capital Expenditures fell 542.52% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year increase of 6705.12%. This contributed to the annual value of $10.6 million for FY2024, which is 2984.63% down from last year.
  • Latest data reveals that Pacira BioSciences reported Capital Expenditures of $3.9 million as of Q3 2025, which was down 542.52% from $2.7 million recorded in Q2 2025.
  • Pacira BioSciences' Capital Expenditures' 5-year high stood at $13.1 million during Q3 2021, with a 5-year trough of $1.6 million in Q2 2024.
  • For the 5-year period, Pacira BioSciences' Capital Expenditures averaged around $6.2 million, with its median value being $5.2 million (2022).
  • Per our database at Business Quant, Pacira BioSciences' Capital Expenditures plummeted by 7099.28% in 2023 and then soared by 20141.04% in 2025.
  • Over the past 5 years, Pacira BioSciences' Capital Expenditures (Quarter) stood at $9.2 million in 2021, then crashed by 40.08% to $5.5 million in 2022, then crashed by 67.26% to $1.8 million in 2023, then rose by 17.8% to $2.1 million in 2024, then skyrocketed by 82.72% to $3.9 million in 2025.
  • Its Capital Expenditures was $3.9 million in Q3 2025, compared to $2.7 million in Q2 2025 and $8.5 million in Q1 2025.